Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

NCT01641666 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Boceprevir
DRUG: Peginterferon Alfa-2b 1.5 mcg/kg/week
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC